Skip to main content

Advertisement

Log in

High-density lipoprotein: Is it always atheroprotective?

Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

High-density lipoproteins (HDLs) are appropriately recognized for their many atheroprotective functions, including reverse cholesterol transport, as well as antioxidant, anti-inflammatory, and antithrombotic effects. Furthermore, the inverse relationship between HDL cholesterol and atherosclerosis is well documented in many populations. However, there is an increasing body of evidence that there are circumstances in which HDL may not be protective, and may in fact paradoxically promote vascular inflammation and oxidation of low-density lipoproteins. Recent studies have provided insight as to specific chemical modifications and structural changes within HDL associated with this phenotype. The presence of proinflammatory HDL coincides with conditions associated with chronic systemic inflammation, including atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Castelli WP, Garrison RJ, Wilson PW, et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986, 256:2835–2838.

    Article  PubMed  CAS  Google Scholar 

  2. Sirtori CR, Calabresi L, Franceschini G, et al.: Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant: The Limone sul Garda Study. Circulation 2001, 103:1949–1954.

    PubMed  CAS  Google Scholar 

  3. Bruce C, Sharp DS, Tall AR: Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998, 39:1071–1078.

    PubMed  CAS  Google Scholar 

  4. Zhong S, Sharp DS, Grove JS, et al.: Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL Levels. J Clin Invest 1996, 97:2917–2923.

    PubMed  CAS  Google Scholar 

  5. Ansell BJ, Navab M, Hama S, et al.: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751–2756.

    Article  PubMed  CAS  Google Scholar 

  6. Asztalos BF, Cupples LA, Demissie S, et al.: High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004, 24:2181–2187.

    Article  PubMed  CAS  Google Scholar 

  7. Brewer HB Jr: High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004, 24:387–391.

    Article  PubMed  CAS  Google Scholar 

  8. Van Lenten BJ, Navab M, Shih D, et al.: The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001, 11:155–161.

    Article  PubMed  Google Scholar 

  9. Ferretti G, Bacchetti T, Negre-Salvayre A, et al.: Structural modifications of HDL and functional consequences. Atherosclerosis 2006, 184:1.

    Article  PubMed  CAS  Google Scholar 

  10. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881–1888.

    Article  PubMed  CAS  Google Scholar 

  11. Cockerill GW, Rye KA, Gamble JR, et al.: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987–1994.

    PubMed  CAS  Google Scholar 

  12. Nofer JR, Kehrel B, Fobker M, et al.: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161:1–16.

    Article  PubMed  CAS  Google Scholar 

  13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Google Scholar 

  14. Navab M, Berliner JA, Subbanagounder G, et al.: HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001, 21:481–488.

    PubMed  CAS  Google Scholar 

  15. Ansell BJ, Watson KE, Fogelman AM, et al.: High-density lipoprotein function: recent advances. J Am Coll Cardiol 2005, 46:1792–1798.

    Article  PubMed  CAS  Google Scholar 

  16. Navab M, Anantharamaiah GM, Reddy ST, et al.: The double jeopardy of HDL. Ann Med 2005, 37:1–6.

    Article  CAS  Google Scholar 

  17. Zaratin AC, Quintao EC, Sposito AC, et al.: Smoking prevents the intravascular remodeling of high-density lipoprotein particles: implications for reverse cholesterol transport. Metabolism 2004, 53:858.

    Article  PubMed  CAS  Google Scholar 

  18. Zago V, Sanguinetti S, Brites F, et al.: Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 2004, 177:203–210.

    Article  PubMed  CAS  Google Scholar 

  19. Sviridov D, Chin-Dusting J, Nestel P, et al.: Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation 2006, 81:361–366.

    Article  PubMed  CAS  Google Scholar 

  20. Tan KC, Chow WS, Lam JC, et al.: HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006, 184:377.

    Article  PubMed  CAS  Google Scholar 

  21. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW: Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999, 19:2226–2233.

    PubMed  CAS  Google Scholar 

  22. Hedrick CC, Thorpe SR, Fu MX, et al.: Glycation impairs high-density lipoprotein function. Diabetologia 2000, 43:312.

    Article  PubMed  CAS  Google Scholar 

  23. Zheng L, Nukuna B, Brennan ML, et al.: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004, 114:529–541.

    Article  PubMed  CAS  Google Scholar 

  24. Nicholls SJ, Zheng L, Hazen SL: Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 2005, 15:212–219.

    Article  PubMed  CAS  Google Scholar 

  25. Shishehbor MH, Aviles RJ, Brennan ML, et al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289:1675–1680.

    Article  PubMed  CAS  Google Scholar 

  26. Zhou T, Zhou SH, Qi SS, et al.: The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 2006, In press.

  27. Wang WQ, Merriam DL, Moses AS, Francis GA: Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers. J Biol Chem 1998, 273:17391–17398.

    Article  PubMed  CAS  Google Scholar 

  28. Panzenbock U, Kritharides L, Raftery M, et al.: Oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein A-I. J Biol Chem 2000, 275:19536–19544.

    Article  PubMed  CAS  Google Scholar 

  29. Khovidhunkit W, Kim MS, Memon RA, et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169–1196.

    Article  PubMed  CAS  Google Scholar 

  30. Rohrer L, Hersberger M, von Eckardstein A: High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004, 15:269–278.

    Article  PubMed  CAS  Google Scholar 

  31. Barter P, Kastelein J, Nunn A, Hobbs R: High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions. Atherosclerosis 2003, 168:195.

    Article  PubMed  CAS  Google Scholar 

  32. Otvos JD, Collins D, Freedman DS, et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556–1563.

    Article  PubMed  CAS  Google Scholar 

  33. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3:144–153.

    Article  PubMed  CAS  Google Scholar 

  34. Nobecourt E, Jacqueminet S, Hansel B, et al.: Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005, 48:529.

    Article  PubMed  CAS  Google Scholar 

  35. Hansel B, Giral P, Nobecourt E, et al.: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004, 89:4963–4971.

    Article  PubMed  CAS  Google Scholar 

  36. Brites FD, Bonavita CD, De Geitere C, et al.: Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000, 152:181–192.

    Article  PubMed  CAS  Google Scholar 

  37. Kontush A, de Faria EC, Chantepie S, Chapman MJ: A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005, 182:277.

    Article  PubMed  CAS  Google Scholar 

  38. Curtiss LK, Bonnet DJ, Rye KA: The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry 2000, 39:5712–5721.

    Article  PubMed  CAS  Google Scholar 

  39. Ribas V, Sanchez-Quesada JL, Anton R, et al.: Human apolipoprotein A-II enrichment displaces paraoxonase from hdl and impairs its antioxidant properties: a new mechanism linking hdl protein composition and antiatherogenic potential. Circ Res 2004, 95:789–797.

    Article  PubMed  CAS  Google Scholar 

  40. Napoli C, D’Armiento FP, Mancini FP, et al.: Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997, 100:2680–2690.

    PubMed  CAS  Google Scholar 

  41. Saely CH, Aczel S, Marte T, et al.: The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005, 90:5698–5703.

    Article  PubMed  CAS  Google Scholar 

  42. Cogny A, Atger V, Paul JL, et al.: High-density lipoprotein 3 physicochemical modifications induced by interaction with human polymorphonuclear leucocytes affect their ability to remove cholesterol from cells. Biochem J 1996, 314(Pt 1):285.

    PubMed  CAS  Google Scholar 

  43. Watson KE, Hama S, Fonarow GC, et al.: Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-inflammatory HDL than dyslipidemic control subjects, even with comparable levels of HDL, hs-CRP and paraoxonase activity. Circulation 2004, 110:III-52.

    Google Scholar 

  44. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685–1695.

    Article  PubMed  CAS  Google Scholar 

  45. Maradit-Kremers H, Nicola PJ, Crowson CS, et al.: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722–732.

    Article  PubMed  Google Scholar 

  46. Roman MJ, Moeller E, Davis A, et al.: Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006, 144:249–256.

    PubMed  Google Scholar 

  47. McMahon MG, Fitzgerald J: Pro-inflammatory HDL as a biomarker for atherosclerosis in SLE and RA. Paper presented at American College of Rheumatology 2005 Annual Scientific Meeting. San Diego, California, 2005.

  48. Van Lenten BJ, Hama SY, de Beer FC, et al.: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96:2758–2767.

    Article  PubMed  Google Scholar 

  49. Van Lenten BJ, Wagner AC, Nayak DP, et al.: High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001, 113:2283–2288.

    Google Scholar 

  50. Duffy D, Rader DJ: Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113:1140–1150.

    Article  PubMed  Google Scholar 

  51. Navab M, Anantharamaiah GM, Reddy ST, et al.: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993–1007.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Benjamin J. Ansell MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ansell, B.J., Fonarow, G.C. & Fogelman, A.M. High-density lipoprotein: Is it always atheroprotective?. Curr Atheroscler Rep 8, 405–411 (2006). https://doi.org/10.1007/s11883-006-0038-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-006-0038-4

Keywords

Navigation